{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:26:20Z","timestamp":1762431980734},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As CAR T-cell therapy has advanced in B-cell acute lymphoblastic leukemia, research is now underway to develop similar therapies for other lymphoid and myeloid malignancies for pediatric patients. Barriers, including antigen selection and on-target\/off-tumor toxicity, have prevented the rapid development of immune-based therapies for T-lineage and myeloid malignancies. More recently, unique strategies have been developed to overcome these barriers, with several products advancing to clinical trials. For T-lineage diseases, targets have focused on CD5, CD7, and CD38, whereas myeloid disease targets have predominately focused on CD123, CD33, and, more recently, CLL-1. This review provides a comprehensive overview of these targets and approaches to overcoming safety concerns in the development of CAR T-cell therapies for pediatric patients with T-lineage and myeloid malignancies.<\/jats:p>","DOI":"10.1182\/hematology.2020000134","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:27:14Z","timestamp":1607138834000},"page":"494-500","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["CAR T cells for other pediatric non\u2013B-cell hematologic malignancies"],"prefix":"10.1182","volume":"2020","author":[{"given":"Adam J.","family":"Lamble","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Seattle Children\u2019s Hospital, Seattle, WA; and"},{"name":"University of Washington School of Medicine, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Gardner","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Seattle Children\u2019s Hospital, Seattle, WA; and"},{"name":"University of Washington School of Medicine, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"25","key":"2020121621255873300_B1","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2020121621255873300_B2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"2020121621255873300_B3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"20","key":"2020121621255873300_B4","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","article-title":"Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group","volume":"27","author":"Burkhardt","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020121621255873300_B5","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"2020121621255873300_B6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/trf.14569","article-title":"Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma","volume":"58","author":"Ceppi","year":"2018","journal-title":"Transfusion"},{"issue":"9","key":"2020121621255873300_B7","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2020121621255873300_B8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary data on safety, cellular kinetics and anti-leukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia [abstract]","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621255873300_B9","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2019-123018","article-title":"Allogeneic anti-CD19 CAR T cells manufactured from healthy donors provide a unique cellular product with distinct phenotypic characteristics compared to CAR T cells generated from patients with mature B cell malignancies [abstract]","volume":"134","author":"Graham","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020121621255873300_B10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"2020121621255873300_B11","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","article-title":"Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia","volume":"133","author":"S\u00e1nchez-Mart\u00ednez","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020121621255873300_B12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/bjh.14310","article-title":"CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy","volume":"180","author":"Bras","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"2020121621255873300_B13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020121621255873300_B14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2020121621255873300_B15","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"issue":"13","key":"2020121621255873300_B16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"2020121621255873300_B17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621255873300_B18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies [abstract]","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2020121621255873300_B19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2020121621255873300_B20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"15 suppl","key":"2020121621255873300_B21","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1200\/JCO.2020.38.15_suppl.3026","article-title":"First-in-human clinical trial of the autologous CD7-CART for relapsed\/refractory ACUTE lymphoblastic leukemia\/lymphoma [abstract]","volume":"38","author":"Zhang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"25","key":"2020121621255873300_B22","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2020121621255873300_B23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"2020121621255873300_B24","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"2020121621255873300_B25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pbc.22612","article-title":"Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study","volume":"55","author":"Gorman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2020121621255873300_B26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bjh.14720","article-title":"Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia","volume":"178","author":"Karlsson","year":"2017","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2020121621255873300_B27","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial [abstract]","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621255873300_B28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial [abstract]","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020121621255873300_B29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T cells for the therapy of acute myeloid leukemia","volume":"27","author":"Gomes-Silva","year":"2019","journal-title":"Mol Ther"},{"issue":"11","key":"2020121621255873300_B30","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/ijms18112259","article-title":"Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia","volume":"18","author":"Laborda","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"3 suppl","key":"2020121621255873300_B31","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/j.bbmt.2018.12.470","article-title":"Optimizing C-type lectin-like molecule 1 (CLL-1) directed CAR T cell therapy of acute myeloid leukemia [abstract]","volume":"25","author":"Atilla","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2020121621255873300_B32","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020121621255873300_B33","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"issue":"4","key":"2020121621255873300_B34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/biomedicines6040110","article-title":"Dissecting the immune landscape of acute myeloid leukemia","volume":"6","author":"Davidson-Moncada","year":"2018","journal-title":"Biomedicines"},{"issue":"23","key":"2020121621255873300_B35","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood.V126.23.852.852","article-title":"Identification of PD1 and TIM3 as checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia [abstract]","volume":"126","author":"Kenderian","year":"2015","journal-title":"Blood"},{"issue":"17","key":"2020121621255873300_B36","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020121621255873300_B37","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"2020121621255873300_B38","doi-asserted-by":"crossref","first-page":"e124430","DOI":"10.1172\/jci.insight.124430","article-title":"Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization","volume":"5","author":"Leung","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"2020121621255873300_B39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"13","key":"2020121621255873300_B40","doi-asserted-by":"crossref","first-page":"e99442","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"2020121621255873300_B41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2020121621255873300_B42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"2020121621255873300_B43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"issue":"20","key":"2020121621255873300_B44","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621255873300_B45","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1182\/blood-2019-127154","article-title":"Use of CD70 targeted chimeric antigen receptor (CAR) T cells for the treatment of acute myeloid leukemia (AML) [abstract]","volume":"134","author":"Leick","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2020121621255873300_B46","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2018.05.014","article-title":"Impact of FLT3 receptor (CD135) detection by flow cytometry on clinical outcome of adult acute myeloid leukemia patients","volume":"18","author":"Kandeel","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2020121621255873300_B47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/gt.2010.21","article-title":"Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther"},{"issue":"22","key":"2020121621255873300_B48","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020121621255873300_B49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/494\/1794818\/hem2020000134c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/494\/1794818\/hem2020000134c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T17:40:39Z","timestamp":1618594839000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/494\/474289\/CAR-T-cells-for-other-pediatric-nonBcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000134","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}